Navigation Links
Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone

Additional Findings Reported Safety & Tolerability Profile in Subjects with Type 2 Diabetes and Healthy Subjects

CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase III data presented this week at the annual meeting of the American Diabetes Association demonstrated that saxagliptin, an inhibitor of dipeptidyl-peptidase-4 (DPP-4) in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), in combination with metformin, exhibited a statistically significant improvement in glycemic control in subjects with Type 2 diabetes compared to metformin alone through 24 weeks of treatment. This was the first time that Phase III data for saxagliptin have been presented in a scientific setting.


A group of 743 subjects (ages 18-77) with Type 2 diabetes whose hemoglobin A1C level was within the range of greater than or equal to 7 percent or less than or equal to 10 percent and on a stable metformin dose alone (1500 to 2550 mg/day) were randomized 1:1:1:1 to add-on saxagliptin 2.5 mg, 5 mg, 10 mg, or placebo once daily. The primary endpoint of the study was the change from baseline in hemoglobin A1C levels. After 24 weeks, the subjects receiving saxagliptin+metformin demonstrated statistically significant decreases in hemoglobin A1C levels compared to placebo+metformin: -0.73 percent, -0.83 percent, and -0.72 percent at the 2.5 mg, 5 mg and 10 mg doses, respectively (p-value at all dosage levels less than 0.0001 vs. placebo+metformin).

Saxagliptin+metformin also statistically significantly reduced fasting plasma glucose (secondary endpoint) as compared to placebo+metformin: -16 mg/dL, -23 mg/dL, and -22 mg/dL for saxagliptin 2.5 mg, 5 mg and 10 mg, respectively (p-value at all dosage levels less than 0.0001 vs. placebo+metformin). The percentage of subjects with hemoglobin A1C less than 7 percent at Week 24 (secondary endpoint) was 17 percent for placebo+metformin and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
5. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
6. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
8. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
(Date:7/24/2014)... 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... a webcast conference call to report its second quarter ... company,s business and outlook on Thursday, August 7, 2014 ... market. The call can be accessed ... five minutes prior to the start of the call ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... market dynamics offers insights into,what will be needed ... to,patients, NEW YORK, May 14, 2007 /PRNewswire-USNewsire/ -- ... a not-for-profit,product development partnership accelerating the discovery and,development ... the first,comprehensive study of the dynamics of the ...
... YORK--(BUSINESS WIRE)--May 15, 2007 - SIGA Technologies, Inc.,(NASDAQ: ... proof of,concept guinea pig trial of its lead ... under Biosafety Level 4 conditions at,the U.S. Army ... Kathleen Cashman under the supervision of Dr.,Mary Guttieri, ...
Cached Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 2SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 3SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 4
(Date:7/24/2014)... For rats bearing human breast tumors, exposure to ... the breast cancer drug tamoxifen, according to data published ... American Association for Cancer Research. The negative effects of ... giving rats a melatonin supplement during the night. , ... with hormone receptor-positive breast cancer," said Steven M. Hill, ...
(Date:7/24/2014)... Voted one of the most reliable ... BellasDress focuses on providing its new and old customers ... the company has announced its new collection of high ... is created according to the latest fashion trends. Additionally, ... 68% off. , As a matter of fact, high ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, ... sub-segments with an in-depth analysis and forecasting of ... for this market with insights on trends, opportunities, ... and 36 figures spread through 157 pages and ... at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers ...
(Date:7/24/2014)... 2014 Just as fitness and health ... their own financial and marketing strength to be important ... to the next level by using the most powerful ... Voice Broadcast, Call Tracking and SMS texting solutions ... text messages are quickly become integral in marketing and ...
(Date:7/24/2014)... (ASAE) announced its 2014 Power of A Award winners, ... Anesthesiologists (ASA). , The ASA Global Humanitarian Outreach ... one of the top honors from ASAE. GHO was ... through education on the global anesthesia crisis and supporting ... was also honored with a Power of A Silver ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3
... By Madonna Behen HealthDay Reporter , MONDAY, ... take erectile dysfunction drugs such as Viagra are more likely ... than 1.4 million men finds. Researchers at Massachusetts General ... lies not with the drugs but rather the high risk ...
... 30 years of standardized test data from the very ... boys and girls have narrowed considerably, but boys still ... high levels of math ability and scientific reasoning. ... extremely high levels of verbal reasoning and writing ability. ...
... ... , ... 2010 -- “Today’s announcement of a new entity at the United Nations for women and ... Harnessing the United Nations’ collective power and authority to advance the rights and needs ...
... , ... Mist Ecology,s AC Spritzer Product and its Parent Company,s Entrepreneurial Engineers , ... (PRWEB) July 6, 2010 -- An engineer goes ... off. Some water splashes on his home,s air conditioning unit, and an idea for a ...
... Get fit with ... July 6-July 19 , ... July 6, 2010 – Onlineshoes.com and New Balance make it easy to get fit ... pedometer from July 6-July 19. (Read on to find out more about New Balance truebalance shoes ...
... ... Air Ambulance is pleased to announce the 2010 Angel MedFlight Scholarship of ... the recipient will receive $3,000 toward his or her tuition for an ... Angel MedFlight Scholarship for Excellence in Aviation only have two more weeks ...
Cached Medicine News:Health News:Drugs Like Viagra Linked to Higher Rates of STDs 2Health News:Drugs Like Viagra Linked to Higher Rates of STDs 3Health News:Gender gap persists at highest levels of math and science testing 2Health News:Gender gap persists at highest levels of math and science testing 3Health News:New UN Entity Strengthens Global Efforts for Women & Girls 2Health News:A/C Mist Device Cools Down Air Conditioners, Utility Bills 2Health News:A/C Mist Device Cools Down Air Conditioners, Utility Bills 3Health News:A/C Mist Device Cools Down Air Conditioners, Utility Bills 4Health News:Onlineshoes.com and New Balance Pair Up for Toning Shoes Giveaway 2Health News:Onlineshoes.com and New Balance Pair Up for Toning Shoes Giveaway 3Health News:Angel MedFlight Worldwide Air Ambulance offers,$3,000 scholarship for a student pursuing a career in aviation at an Arizona school, 2Health News:Angel MedFlight Worldwide Air Ambulance offers,$3,000 scholarship for a student pursuing a career in aviation at an Arizona school, 3
... 30in(w) x 24in(d) x 24in(h). Designed ... amplification reactions. The PCR Workstation irradiates ... against cross or airborne contamination by limiting ... enviornment. Includes two fluorescent lights, one ...
... for highthroughput reading of tube racks. Its camera-based ... than one second per rack, making it ideal ... of the reader allows a rack to be ... robotic arms. An optical safety switch prevents a ...
Reads single TrakMates tubes instantly, and drops decoded tube number instantly into any Windows application. System includes reader and Windows based software....
... Polypropylene workbench top with ... adjustable from 25"-34". Available in ... Accessories include shelves, drawers, light ... is an expert in custom ...
Medicine Products: